couple quick follow ups:
"Genentech plans to open an Expanded Access Program (EAP) in the United States to provide, under certain circumstances, people with HER2-positive mBC access to trastuzumab emtansine while the company seeks regulatory approval."
http://www.gene.com/gene/news/press-...etail&id=14147
"Based on these updated overall survival results, people in the lapatinib and Xeloda arm of EMILIA will be offered the option to receive trastuzumab emtansine"
http://www.roche.com/media/media_rel...2012-08-27.htm